Indoco Remedies posted sales of Rs276cr vs. Rs248cr in 2QFY16, up by 11.6% yoy,
mainly on back of domestic sales (Rs168.8cr, which grew by 22.0% yoy). Overall,
the formulations, which posted sales of RS261.4cr grew, by 13.0% yoy. The
API (Rs135.9cr) dipped by 11.0% yoy. On the operating front, the gross margin
came in at 64.9% (65.0% expected) vs. 64.4% in 2QFY2016, with EBIDTA margin
coming in at 13.5% (15.5% expected) vs. 15.5% in 2QFY2016. Consequently, the
PAT came in at Rs22.1cr vs. Rs21.5cr, a yoy growth of 2.7%. This was against the
expectations of Rs25cr. We maintain our reduce rating on the stock, on back of
expensive valuations.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...